These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6812406)

  • 1. Antiarrhythmic, antifibrillatory, and hemodynamic actions of bethanidine sulfate: an orally effective analog of bretylium for suppression of ventricular tachyarrhythmias.
    Bacaner MB; Benditt DG
    Am J Cardiol; 1982 Oct; 50(4):728-34. PubMed ID: 6812406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiarrhythmic and electrophysiologic actions of bethanidine sulfate in primary ventricular fibrillation or life-threatening ventricular tachycardia.
    Benditt DG; Benson DW; Dunnigan A; Kriett JM; Pritzker MR; Bacaner MB
    Am J Cardiol; 1984 May; 53(9):1268-74. PubMed ID: 6711426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of ventricular fibrillation and positive inotropic action of bethanidine sulfate, a chemical analog of bretylium tosylate that is well absorbed orally.
    Bacaner MB; Hoey MF; Macres MG
    Am J Cardiol; 1982 Jan; 49(1):45-55. PubMed ID: 7053610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bethanidine sulfate: efficacy in prevention of ventricular tachyarrhythmias during programmed stimulation. Report of a multicenter study of 56 patients.
    Teichman SL; Waspe LE; Matos JA; Kim SG; Fisher JD
    J Am Coll Cardiol; 1985 Sep; 6(3):510-7. PubMed ID: 3897340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ischemia-induced conduction delay and ventricular arrhythmias: comparative electropharmacology of bethanidine sulfate and bretylium tosylate.
    Kabell G
    J Cardiovasc Pharmacol; 1989 Mar; 13(3):471-82. PubMed ID: 2471895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute electrophysiologic effects of bethanidine sulfate in patients with ventricular tachycardia or fibrillation.
    DiMarco JP; Sellers TD; Shipe JR; Savory J; Spyker DH
    Am Heart J; 1984 Nov; 108(5):1244-9. PubMed ID: 6496282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bethanidine sulfate in paroxysmal ventricular tachycardia: toxicity and antifibrillatory actions.
    Bauman JL; Gallastegui J; Prechel D; Anderson JL
    Pharmacotherapy; 1986; 6(4):184-92. PubMed ID: 3774563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of ventricular tachyarrhythmias in the conscious canine during the recovery phase of experimental ischemic injury: effect of bethanidine administration.
    Patterson E; Amalfitano DJ; Lucchesi BR
    J Cardiovasc Pharmacol; 1984; 6(3):470-5. PubMed ID: 6202974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bretylium tosylate: profile of the only available class III antiarrhythmic agent.
    Anderson JL
    Clin Ther; 1985; 7(2):205-24. PubMed ID: 3886143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiarrhythmic action of bethanidine.
    Somberg JC; Butler B; Torres V; Flowers D; Tepper D; Wynn J; Keren G; Miura DS
    Am J Cardiol; 1984 Aug; 54(3):343-6. PubMed ID: 6465015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bretylium tosylate: a newly available antiarrhythmic drug for ventricular arrhythmias.
    Heissenbuttel RH; Bigger JT
    Ann Intern Med; 1979 Aug; 91(2):229-38. PubMed ID: 380436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meobentine sulfate: antiarrhythmic and electrophysiologic effects assessed by programmed electrical stimulation and ambulatory monitoring in patients with complex ventricular tachyarrhythmia. Report of a multicenter evaluation.
    Anderson JL; Reid PR; Platia EV; Akhtar M; Ruskin JN; Schaal SF; Jueng P; Long RA; Wenger TL
    Am Heart J; 1985 Oct; 110(4):774-84. PubMed ID: 3901715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of chronic canine ventricular tachyarrhythmias with bretylium tosylate.
    Patterson E; Gibson JK
    Circulation; 1981 Nov; 64(5):1045-50. PubMed ID: 7285294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dual electrophysiologic test for atrial antireentry and ventricular antifibrillatory studies. Effects of bethanidine, procainamide, and WY-48986.
    Wu KM; Hunter TL; Proakis AG
    J Pharmacol Methods; 1990 Apr; 23(2):87-95. PubMed ID: 2332983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bretylium tosylate: a review.
    Bryan CK; Darby MH
    Am J Hosp Pharm; 1979 Sep; 36(9):1189-92. PubMed ID: 386786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical suppression of refractory ventricular tachycardia with oral bretylium not predicted by electrophysiologic drug testing.
    Grubb BP; Luck JC; Bacaner M
    Chest; 1988 Aug; 94(2):430-2. PubMed ID: 3396427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symposium on the management of ventricular dysrhythmias. Antifibrillatory versus antiectopic therapy.
    Anderson JL
    Am J Cardiol; 1984 Jul; 54(2):7A-13A. PubMed ID: 6147079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of intravenous and oral bretylium tosylate in survivors of ventricular tachycardia or fibrillation: clinical application of a new assay for bretylium.
    Anderson JL; Patterson E; Wagner JG; Johnson TA; Lucchesi BR; Pitt B
    J Cardiovasc Pharmacol; 1981; 3(3):485-99. PubMed ID: 6168830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bretylium tosylate in the management of recurrent ventricular fibrillation complicating acute myocardial infarction.
    Dhurandhar RW; Pickron J; Goldman AM
    Heart Lung; 1980; 9(2):265-70. PubMed ID: 6898604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of bretylium to suppress inducible ventricular tachycardia.
    Greene HL; Werner JA; Gross BW; Sears GK
    Am Heart J; 1983 May; 105(5):717-21. PubMed ID: 6846114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.